Reproxalap on track to supplant steroids for patients with uveitis

Physicians may soon have a steroid alternative in their uveitis treatment toolkit: A phase 2 trial finds that the new aldehyde trap drug reproxalap (Aldeyra Therapeutics) is noninferior to prednisolone acetate (Pred Forte) at reducing ocular inflammation in patients with noninfectious anterior uveitis.
Source: AAO

Posted in: Practice News

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553